Louise Nicolin - Enzymatica Publ Director

ENZY Stock  SEK 3.20  0.13  4.23%   

Director

Ms. Louise Nicolin was Director of Enzymatica AB since December 19, 2016. She is also Chairman of Better Business World Wide and board member of Volati AB, VBG Group AB, Uppdragshuset Sverige AB. She also holds board appointments within Dellner Couplers Group. Since 2000 Louise is active in Nicolin Consulting AB, focusing on business development and quality assurance and she is also a former business manager and senior consultant at PlantVision. She holds M.Sc. in Molecular Biotechnology from Uppsala University and Exc. MBA. since 2016.
Age 46
Tenure 8 years
Professional MarksMBA
Phone46 4 62 86 31 00
Webhttps://www.enzymatica.se

Enzymatica Publ Management Efficiency

The company has return on total asset (ROA) of (0.1909) % which means that it has lost $0.1909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4032) %, meaning that it generated substantial loss on money invested by shareholders. Enzymatica Publ's management efficiency ratios could be used to measure how well Enzymatica Publ manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.12 M in total debt with debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. Enzymatica Publ AB has a current ratio of 2.04, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Enzymatica Publ until it has trouble settling it off, either with new capital or with free cash flow. So, Enzymatica Publ's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enzymatica Publ AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enzymatica to invest in growth at high rates of return. When we think about Enzymatica Publ's use of debt, we should always consider it together with cash and equity.
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden. Enzymatica operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 24 people. Enzymatica Publ AB (ENZY) is traded on Stockholm Exchange in Sweden and employs 23 people.

Management Performance

Enzymatica Publ AB Leadership Team

Elected by the shareholders, the Enzymatica Publ's board of directors comprises two types of representatives: Enzymatica Publ inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzymatica. The board's role is to monitor Enzymatica Publ's management team and ensure that shareholders' interests are well served. Enzymatica Publ's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzymatica Publ's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jonas Forsberg, Director
Bengt Baron, Independent Chairman of the Board
Mats Clarsund, Executive Vice President for Research and Development
Stefan Olsson, Communication Mang
Anders Jungbeck, Director
Nils Siegbahn, Director
Bengt Jondell, Acting CFO
Claus Egstrand, Chief Commercial Officer
Sigurgeir Gudlaugsson, Director
Ulf Blom, Executive Vice President Marketing and Operations
Gun Rydhog, Director of Quality and Regulatory Management
Louise Nicolin, Director
Anna Isaksson, Vice President Quality and Regulatory Management
Therese Filmersson, Chief Financial Officer
Monica Wallter, Director
Marianne Alexandersson, Independent Director
Hans Pihl, Director
Gudmundur Palmason, Director
Jorgen Rexo, Executive Vice President Legal, Director
Mats Andersson, Director
Fredrik Lindberg, Chief Executive Officer
Lennart Nilsson, Chairman of the Board
Johan Lindvall, Chief Operating Officer, Executive Vice President
Johan Wennerholm, CFO

Enzymatica Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enzymatica Publ a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Enzymatica Publ

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enzymatica Publ position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzymatica Publ will appreciate offsetting losses from the drop in the long position's value.

Moving against Enzymatica Stock

  0.86SHB-B Svenska HandelsbankenPairCorr
  0.85SHB-A Svenska HandelsbankenPairCorr
  0.8SEB-A Skandinaviska EnskildaPairCorr
  0.65VOLV-A AB VolvoPairCorr
  0.64VOLV-B AB VolvoPairCorr
The ability to find closely correlated positions to Enzymatica Publ could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enzymatica Publ when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enzymatica Publ - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enzymatica Publ AB to buy it.
The correlation of Enzymatica Publ is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enzymatica Publ moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enzymatica Publ AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enzymatica Publ can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enzymatica Publ AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Enzymatica Stock analysis

When running Enzymatica Publ's price analysis, check to measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Please note, there is a significant difference between Enzymatica Publ's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enzymatica Publ is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enzymatica Publ's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.